Chugai Pharmaceutical Co., Ltd. (FRA:CUP)

Market Cap	69.45B +9.2%
Revenue (ttm)	7.04B +5.7%
Net Income	2.47B +10.3%
EPS	1.50 +10.2%
Shares Out	n/a
PE Ratio	28.16
Forward PE	n/a
Dividend	1.54 (3.58%)
Ex-Dividend Date	Dec 29, 2025

Volume	n/a
Average Volume	13
Open	43.49
Previous Close	41.54
Day's Range	43.49 - 43.49
52-Week Range	33.02 - 56.26
Beta	n/a
RSI	40.18
Earnings Date	Apr 24, 2026

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular...

• Industry: Pharmaceutical Preparations
• Founded: 1925
• Employees: 5,104
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CUP

Financial Performance

In 2025, Chugai Pharmaceutical's revenue was 1.26 trillion, an increase of 7.46% compared to the previous year's 1.17 trillion. Earnings were 434.01 billion, an increase of 12.06%.

Financial numbers in JPY